Incubate Coalition

In a recent opinion piece, Incubate Executive Director John Stanford and Senator Thom Tillis (R-NC) took to the pages of Fortune with a clear warning: America’s leadership in life sciences innovation is not guaranteed. Policies that undermine intellectual property protections, distort market incentives, or inject uncertainty into the biotech ecosystem risk driving investment -- and the next generation of cures -- overseas. As global competitors aggressively court biotech capital and talent,...

WASHINGTON (April 21) -- Today, Incubate, in partnership with Manatt Health, released new insights from interviews with leading biopharmaceutical investors showing that instability at the Food and Drug Administration (FDA) is increasingly shaping investment decisions. In short, investors aren't just evaluating science -- they're reassessing whether the U.S. regulatory environment is predictable enough to support it. Based on interviews with 16 investors spanning seed, venture, and private...

WASHINGTON (April 13) -- Today, President Trump signed into law the Small Business Innovation and Economic Security Act , which reauthorizes the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs through 2031. Incubate Executive Director John Stanford issued the following statement: "The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are lifelines for early-stage biotech startups. We commend...